Augustinsson L E, Blennow K, Blomstrand C, Bråne G, Ekman R, Fredman P, Karlsson I, Kihlgren M, Lehmann W, Lekman A, Månsson J E, Ramström I, Wallin A, Wikkelsö C, Gottfries C G, Svennerholm L
Department of Clinical Neuroscience, Göteborg University, Sweden.
Dement Geriatr Cogn Disord. 1997 Jan-Feb;8(1):26-33. doi: 10.1159/000106597.
We have conducted a preliminary study of the optimum conditions for a therapeutic effect of ganglioside GM1 in Alzheimer's disease. Five patients with the early onset form of Alzheimer's disease (AD type I) received the ganglioside by intracerebroventricular administration for 12 months. Bilateral stereotactic punction of the frontal horns of the ventricular system was performed, and shunt catheters were implanted and connected to a programmable pump. The optimum GM1 dose varied between 20 and 30 mg/24 h. Neurological neuropsychological, psychiatric and neurochemical examinations were performed 7 days before surgery and on days 30, 90, 180 and 360. No patient found the surgery difficult and no patient or relative regretted that they participated in the study. The patients became more active and safer in relation to others and to performance of various activities from day 90. The cerebrospinal fluid level of the monoamine metabolites homovanillic acid and 5-hydroxyindoleacetic acid and the neuropeptide somatostatin increased.
我们已对神经节苷脂GM1治疗阿尔茨海默病的最佳疗效条件进行了初步研究。5例早发型阿尔茨海默病（I型AD）患者通过脑室内给药接受神经节苷脂治疗12个月。对脑室系统额角进行双侧立体定向穿刺，植入分流导管并连接到可编程泵。GM1的最佳剂量在20至30mg/24小时之间。在手术前7天以及第30、90、180和360天进行神经、神经心理学、精神和神经化学检查。没有患者觉得手术困难，也没有患者或其亲属后悔参与该研究。从第90天起，患者在与他人相处及进行各种活动时变得更加活跃且更安全。单胺代谢产物高香草酸和5-羟吲哚乙酸以及神经肽生长抑素的脑脊液水平升高。
